Overview
Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2021-12-01
2021-12-01
Target enrollment:
66
66
Participant gender:
All
All
Summary
The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus. The reported symptoms vary from fever or chills, cough, shortness of breath, to muscle aches, headaches, loss of taste or smell. The hard capsule KOVIR is a product based on the traditional medicine named "Nhân sâm bài độc táng" which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Sunstar Joint Stock CompanyCollaborator:
Big Leap Clinical Research Joint Stock Company
Criteria
Inclusion Criteria:- Male or female, age from 18 to 65 years old, Vietnamese nationality
- Participants diagnosed with Positive result of SARS-CoV-2 using real time RT-PCR test,
Ct value <30 (equivalent to viral load > 3log)
- Voluntary participation in the study by signing an informed consent
- Ability to adhere to treatment according to the investigator's assessment
Exclusion Criteria:
- Symptoms of severe upper and lower respiratory tract infections such as dyspnea,
SpO2<93%.
- Acute reduction of ventilation function of respiratory apparatus and/or respiration
function of the lung in any of the following three groups:
- Respiratory distress due to hypoxemia with PaO2 less than 60mmHg when breathing
room air.
- Respiratory distress due to hypercapnia with PaCO2 above 50mmHg
- Mixed respiratory distress accompanied by both a decrease in PaO2 and an increase
in PaCO2
- Allergy/intolerance to any component of the study drug.
- Inability to administer medicine.
- Severe pneumonia as assessed by the investigator.
- Inability to comply with study procedures or to ensure compliance with study drug
administration as assessed by investigators.